Sökning: onr:"swepub:oai:DiVA.org:oru-54872" >
Sexual dysfunction ...
Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer
-
- Baumgart, Juliane, 1978- (författare)
- Örebro universitet,Institutionen för hälsovetenskap och medicin,Region Örebro län,Department of Obstetrics and Gynecology, Örebro University Hospital, Örebro
-
- Nilsson, Kerstin, 1953- (författare)
- Örebro universitet,Institutionen för hälsovetenskap och medicin,Region Örebro län,Department of Obstetrics and Gynecology, Örebro University Hospital, Örebro
-
- Stavreus-Evers, Anneli, 1955- (författare)
- Uppsala universitet,Obstetrik & gynekologi,Klinisk och experimentell reproduktionsbiologi/Olovsson
-
visa fler...
-
- Kallak, Theodora Kunovac, 1985- (författare)
- Uppsala universitet,Obstetrik & gynekologi,Klinisk och experimentell reproduktionsbiologi/Olovsson
-
- Sundström Poromaa, Inger (författare)
- Uppsala universitet,Obstetrik & gynekologi,Reproduktiv hälsa/Sundström Poromaa
-
visa färre...
-
(creator_code:org_t)
- Lippincott Williams & Wilkins, 2013
- 2013
- Engelska.
-
Ingår i: Menopause. - : Lippincott Williams & Wilkins. - 1072-3714 .- 1530-0374. ; 20:2, s. 162-168
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
https://urn.kb.se/re...
-
visa färre...
Abstract
Ämnesord
Stäng
- Objective: The goal of this study was to investigate sexual function in postmenopausal breast cancer patients treated with aromatase inhibitors.Methods: A population-based, cross-sectional study was conducted among postmenopausal breast cancer patients on adjuvant endocrine treatment and age-matched controls with and without estrogen treatment. Sexual function was assessed with a standardized questionnaire.Results: In all, 42.4% of aromatase inhibitor-treated breast cancer patients were dissatisfied with their sex life in general, and 50.0% reported low sexual interest; this was significantly more common than in tamoxifen-treated patients and controls (P < 0.05). Aromatase inhibitorYtreated patients reported insufficient lubrication in 73.9% and dyspareunia in 56.5% of cases, which were significantly more common than in controls, irrespective of hormonal use (P < 0.05). Tamoxifen-treated patients reported significantly more dyspareunia (31.3%; P < 0.05) but resembled controls in all other concerns.Conclusions: Our findings suggest that sexual dysfunction in aromatase inhibitorYtreated women is a greatly underestimated problem.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Allmänmedicin (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- General Practice (hsv//eng)
Nyckelord
- Aromatase inhibitors
- Breast cancer
- Postmenopausal women
- Sexual dysfunction
- Tamoxifen
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas